AndreaBozzo/ceres-open-data-index huggingface dataset:
Asymmetric interactions in the adenosine-binding pockets of the MS2 coat protein dimer

Background
          The X-ray structure of the MS2 coat protein-operator RNA complex reveals the existence of quasi-synmetric interactions of adenosines -4 and -10 in pockets formed on different subunits of the coat protein dimer. Both pockets utilize the same five amino acid residues, namely Val29, Thr45, Ser47, Thr59, and Lys61. We call these sites the adenosine-binding pockets.
        
        
          Results
          We present here a heterodimer complementation analysis of the contributions of individual A-pocket amino acids to the binding of A-4 and A-10 in different halves of the dimer. Various substitutions of A-pocket residues were introduced into one half of single-chain coat protein heterodimers where they were tested for their abilities to complement Y85H or T91I substitutions (defects in the A-4 and A-10 half-sites, respectively) present in the other dimer half.
        
        
          Conclusions
          These experiments provide functional tests of interactions predicted from structural analyses, demonstrating the importance of certain amino acid-nucleotide contacts observed in the crystal structure, and showing that others make little or no contribution to the stability of the complex. In summary, Val29 and Lys61 form important stabilizing interactions with both A-4 and A-10. Meanwhile, Ser47 and Thr59 interact primarily with A-10. The important interactions with Thr45 are restricted to A-4.
Compound 528800: Cyclotritriacontasiloxane, hexahexacontamethyl

Chemical compound data from PubChem database. IUPAC Name: 2,2,4,4,6,6,8,8,10,10,12,12,14,14,16,16,18,18,20,20,22,22,24,24,26,26,28,28,30,30,32,32,34,34,36,36,38,38,40,40,42,42,44,44,46,46,48,48,50,50,52,52,54,54,56,56,58,58,60,60,62,62,64,64,66,66-hexahexacontamethyl-1,3,5,7,9,11,13,15,17,19,21,23,25,27,29,31,33,35,37,39,41,43,45,47,49,51,53,55,57,59,61,63,65-tritriacontaoxa-2,4,6,8,10,12,14,16,18,20,22,24,26,28,30,32,34,36,38,40,42,44,46,48,50,52,54,56,58,60,62,64,66-tritriacontasilacyclohexahexacontane. Molecular Formula: C66H198O33Si33. Molecular Weight: 2447.1. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 529006: Isobutyl 3-hydroxybutanoate

Chemical compound data from PubChem database. IUPAC Name: 2-methylpropyl 3-hydroxybutanoate. Molecular Formula: C8H16O3. Molecular Weight: 160.21. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
U.S. State and Territorial Orders Closing and Reopening Bars Issued from March 11, 2020 through August 15, 2021 by County by Day

State and territorial executive orders, administrative orders, resolutions, and proclamations are collected from government websites and cataloged and coded using Microsoft Excel by one coder with one or more additional coders conducting quality assurance.

Data were collected to determine when bars in states and territories were subject to closing and reopening requirements through executive orders, administrative orders, resolutions, and proclamations for COVID-19. Data can be used to determine when bars in states and territories were subject to closing and reopening requirements through executive orders, administrative orders, resolutions, and proclamations for COVID-19. Data consists exclusively of state and territorial orders, many of which apply to specific counties within their respective state or territory; therefore, data is broken down to the county level.

These data are derived from publicly available state and territorial executive orders, administrative orders, resolutions, and proclamations (“orders”) for COVID-19 that expressly close or reopen bars found by the CDC, COVID-19 Community Intervention & Critical Populations Task Force, Monitoring & Evaluation Team, Mitigation Policy Analysis Unit, and the CDC, Center for State, Tribal, Local, and Territorial Support, Public Health Law Program from March 11, 2020 through August 15, 2021.  These data will be updated as new orders are collected. Any orders not available through publicly accessible websites are not included in these data. Only official copies of the documents or, where official copies were unavailable, official press releases from government websites describing requirements were coded; news media reports on restrictions were excluded. Recommendations not included in an order are not included in these data. Effective and expiration dates were coded using only the date provided; no distinction was made based on the specific time of the day the order became effective or expired. These data do not necessarily represent an official position of the Centers for Disease Control and Prevention.
Compound 528181: 1,3-Cyclopentadiene, 2-pentyl

Chemical compound data from PubChem database. IUPAC Name: 2-pentylcyclopenta-1,3-diene. Molecular Formula: C10H16. Molecular Weight: 136.23. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528059: His, TBDMS

Chemical compound data from PubChem database. IUPAC Name: [tert-butyl(dimethyl)silyl] 2-[[tert-butyl(dimethyl)silyl]amino]-3-(1H-imidazol-5-yl)propanoate. Molecular Formula: C18H37N3O2Si2. Molecular Weight: 383.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
SHIP Uninsured ED Visits 2008-2017

This is historical data. The update frequency has been set to "Static Data" and is here for historic value. Updated on 8/14/2024

Uninsured ED Visits - This indicator shows the percentage of persons without health (medical) insurance who seek care through the Emergency Department. People without health insurance are more likely to be in poor health than the insured. Lack of health insurance can result in increased visits to the emergency department and decreased routine care visits with a primary care provider.
MD COVID-19 - Confirmed Deaths by Age Distribution

<b>Note:</b> Starting April 27, 2023 updates change from daily to weekly.

<b>Summary</b>
The cumulative number of confirmed COVID-19 deaths among Maryland residents by age: 0-9; 10-19; 20-29; 30-39; 40-49; 50-59; 60-69; 70-79; 80+; Unknown.

<b>Description</b>
The MD COVID-19 - Confirmed Deaths by Age Distribution data layer is a collection of the statewide confirmed COVID-19 related deaths that have been reported each day by the Vital Statistics Administration by designated age ranges. A death is classified as confirmed if the person had a laboratory-confirmed positive COVID-19 test result. Some data on deaths may be unavailable due to the time lag between the death, typically reported by a hospital or other facility, and the submission of the complete death certificate. Probable deaths are available from the MD COVID-19 - Probable Deaths by Age Distribution data layer.

<b>Terms of Use</b>
The Spatial Data, and the information therein, (collectively the "Data") is provided "as is" without warranty of any kind, either expressed, implied, or statutory. The user assumes the entire risk as to quality and performance of the Data. No guarantee of accuracy is granted, nor is any responsibility for reliance thereon assumed. In no event shall the State of Maryland be liable for direct, indirect, incidental, consequential or special damages of any kind. The State of Maryland does not accept liability for any damages or misrepresentation caused by inaccuracies in the Data or as a result to changes to the Data, nor is there responsibility assumed to maintain the Data in any manner or form. The Data can be freely distributed as long as the metadata entry is not modified or deleted. Any data derived from the Data must acknowledge the State of Maryland in the metadata.
San Francisco – SF Div: Drug-Related Emergency Department Visits, 2004-2011 - Adverse Reactions

Excel file with estimates, rates, relative standard errors, trends and confidence intervals, covering 2004-2011 for emergency department visits involving adverse reactions in the San Francisco metropolitan area, San Francisco division. It includes ED visits in which an adverse health consequence (e.g., side effects or an allergic reaction) resulted when taking prescription drugs, over-the-counter medications, or dietary supplements as prescribed or recommended.  This analytic category does not include drug misuse or abuse.File includes data for over 500 drugs, including illicit drugs, prescription and over-the-counter medications, dietary supplements, inhalants and alcohol.  Includes total visits, gender, age group, race/ethnicity, outcome of visit, drug combinations, number of drugs involved in visit, drug frequency, and drugs confirmed by toxicology.Additional detail is provided for illicit drugs, psychotherapeutic drugs, central nervous system (CNS) drugs, respiratory drugs and cardiovascular drugs.
Compound 529433: 2,8-Dimethyl-5-propan-2-yl-1,2,4,7,8,8a-hexahydroazulene

Chemical compound data from PubChem database. IUPAC Name: 2,8-dimethyl-5-propan-2-yl-1,2,4,7,8,8a-hexahydroazulene. Molecular Formula: C15H24. Molecular Weight: 204.35. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Weekly Cumulative Influenza Vaccination Coverage, Children 6 months through 17 years, United States

Weekly Cumulative Influenza Vaccination Coverage, Children 6 months through 17 years, United States

• Archived data are available here:  https://data.cdc.gov/resource/vfj2-bfuw 
• Influenza vaccination coverage among children is assessed through the National Immunization Survey-Flu (NIS-Flu) annually, providing weekly influenza vaccination coverage estimates for children 6 months–17 years based upon parental report. (https://www.cdc.gov/vaccines/imz-managers/nis/about.html)
o NIS-Flu is a national random-digit-dialed cellular telephone survey of households conducted during the flu season (October-June).
• Final estimates for prior seasons and other flu vaccination data are available at CDC’s FluVaxView:  https://www.cdc.gov/flu/fluvaxview/index.htm.
Patent AT-E399555-T1: [Translated] TREATMENT OF RHEUMATOID ARTHRITIS WITH IMITANIB

4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I or a pharmaceutically acceptable salt thereof can be used in the treatment of rheumatoid arthritis. The invention also relates to a combination of the compound of the formula I or a pharmaceutically acceptable salt thereof with one or more disease modifying arthritis rheumatoid drugs (DMARDs).
Compound 529061: 2,4,5-Trithiahexane, 3-(2-methylpropyl)

Chemical compound data from PubChem database. IUPAC Name: 3-methyl-1-(methyldisulfanyl)-1-methylsulfanylbutane. Molecular Formula: C7H16S3. Molecular Weight: 196.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Tribal Courts and Child Welfare: Adapting to Child Welfare Cases

This Child Welfare Information Gateway Podcast is available on Apple Podcasts
  
  

, GooglePlay
  
  

, Spotify
  
  

, Stitcher
  
  

, SoundCloud
  
  

, and the Child Welfare Information Gateway
  
  

 website. Subscribe to receive new episodes as they are released.

Metadata-only record linking to the original dataset. Open original dataset below.
Payroll Based Journal Daily Non-Nurse Staffing

The Payroll Based Journal (PBJ) Nurse Staffing and Non-Nurse Staffing datasets provide information submitted by nursing homes including rehabilitation services on a quarterly basis. The data include the hours staff are paid to work each day, for each facility. Examples of reporting categories include Director of Nursing, Administrative Registered Nurses, Registered Nursing, Administrative Licensed Practice Nurses, Licensed Practice Nurses, Certified Nurse Aides, Certified Medication Aides, and Nurse Aides in Training. There are also other non-nurse staff categories provided in the data such as Respiratory Therapist, Occupational Therapist, and Social Worker. The datasets also include a facility’s daily census calculated using the Minimum Data Set (MDS) submission.
2019 NSDUH Detailed Tables

Get detailed national estimates from the 2018 and 2019 National Surveys on Drug Use and Health (NSDUH). The tables provide comprehensive statistics on substance use, mental health, and treatment in the United States. Longer-term trends are also available for select indicators.The tables are based on the NSDUH survey, which interviews people ages 12 or older in the civilian, noninstitutionalized population. In the tables, indicators are broken out by a variety of demographic, geographic, and economic variables.The following topics are covered, among others: drug, alcohol, nicotine, and tobacco product use and initiation; substance use disorder (SUD); substance use risk and protective factors; availability of substance use treatment; any mental illness (AMI) and serious mental illness (SMI); major depressive episode (MDE); suicidal thoughts and behaviors; serious psychological distress (SPD); mental health service utilization; treatment for depression; and co-occurrence of mental health issues and SUDs.All of the tables can be downloaded in a zip file which contains both an html and PDF file containing every table. Alternatively, users can open the clickable Table of Contents to go to a particular section. Click on “PE” to get to a population estimate or percentage table, and “SE” to get a standard error table.
Patent AT-E400930-T1: [Translated] RADIO NETWORK CONTROL USING MOBILE TRANSMIT POWER ON THE UPLINK

A mobile station's current uplink transmit power capacity is taken into account in radio resource allocation decision and in other radio network operations. Once a user connection between a mobile station and the radio network is established, the current transmit power level of the mobile station is detected. Information regarding that detected power level is provided to the radio network for use in one or more radio control operations such as admission control operations. Examples of such admission control operations include bit rate changes, handover, and power/interference regulation. The information regarding the detected uplink power level is preferably included with an uplink message otherwise already transmitted from the mobile station to the radio network on a regular basis. In a preferred example embodiment, a radio network control node determines an amount of radio coverage for the mobile station based on the provided uplink, mobile transmit power level information. The radio network control node decides whether to change some aspect of the user connection based on that coverage determination. Other radio related parameters may be considered in the decision such as the current interference level in a particular cell. The radio network controller may decide, for example, whether a first bit rate currently assigned to the user connection can be changed to a second higher bit rate or if a handover to a neighboring cell can be accommodated without the user connection being lost or deteriorated as a result.
MD COVID-19 - Cases by County

<b>Note:</b> Starting April 27, 2023 updates change from daily to weekly.

<b>Summary</b>
The cumulative number of positive COVID-19 cases among Maryland residents within a single Maryland jurisdiction.

<b>Description</b>
The MD COVID-19 - Cases by County data layer is a collection of positive COVID-19 test results that have been reported each day by the local health department via the ESSENCE system.

<b>Terms of Use</b>
The Spatial Data, and the information therein, (collectively the "Data") is provided "as is" without warranty of any kind, either expressed, implied, or statutory. The user assumes the entire risk as to quality and performance of the Data. No guarantee of accuracy is granted, nor is any responsibility for reliance thereon assumed. In no event shall the State of Maryland be liable for direct, indirect, incidental, consequential or special damages of any kind. The State of Maryland does not accept liability for any damages or misrepresentation caused by inaccuracies in the Data or as a result to changes to the Data, nor is there responsibility assumed to maintain the Data in any manner or form. The Data can be freely distributed as long as the metadata entry is not modified or deleted. Any data derived from the Data must acknowledge the State of Maryland in the metadata.
Patent AT-E400564-T1: [Translated] PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS

A class of benzodihydrofuran compounds having the structure of formula (I) below and pharmaceutically acceptable salts thereof are useful as therapeutic compounds, particularly in the treatment of hyperlipidemia, hypercholesterolemia, dyslipidemia, and other lipid disorders, and in delaying the onset of or reducing the risk of conditions and sequelae that are associated with these diseases, such as atherosclerosis.
NCHS Rapid Survey Systems Restricted Use File

The NCHS Rapid Surveys System includes questions sponsored by CDC programs and other partners to address time-sensitive data needs, public health attitudes or behaviors, and developmental work to improve concept measurement and inform future question design. It also includes standard variables used for sample weighting and calibration, as well as selected portions of existing content from NCHS surveys (such as the National Health Interview Survey) to compare panel estimates to these benchmarks, assess the fitness-for-use of the panel survey data, and for other methodological purposes.
Publications Using SAMHSA DataNational Directory of Mental Health Treatment Facilities

TheNational Directory of Mental Health Treatment Facilities - 2021is a listing of federal, state, and local government facilities and private facilities that provide mental health treatment services. It includes treatment facilities that responded to the 2020 National Mental Health Services Survey (N-MHSS). The information about each facility that appears in this Directory was provided by that facility in response to the 2020 N-MHSS. The N-MHSS is conducted annually by the Substance Abuse and Mental Health Services Administration (SAMHSA).The Directory is ordered alphabetically by state, by city within each state, and by facility name within each city. Each facility listing includes codes that represent the services offered and other features of the facility, including codes that indicate services for hearing impaired and non-English-speaking clients. Codes are defined in a key shown on pages v-ix. Because the services offered by a particular facility may change over time, it is always a good idea to verify the information in this Directory when contacting a facility.
Compound 526237: 1,2,4,6,7,8-Hexabromo-dibenzofuran

Chemical compound data from PubChem database. IUPAC Name: 1,2,4,6,7,8-hexabromodibenzofuran. Molecular Formula: C12H2Br6O. Molecular Weight: 641.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528044: 1-[10,13-dimethyl-3,11-bis(trimethylsilyloxy)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethoxy-trimethylsilane

Chemical compound data from PubChem database. IUPAC Name: 1-[10,13-dimethyl-3,11-bis(trimethylsilyloxy)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethoxy-trimethylsilane. Molecular Formula: C30H60O3Si3. Molecular Weight: 553.0. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
2020 Triennial Process Evaluation Report Of The Projects For Assistance In Transition From Homelessness Program (PATH)

SAMHSA’s Projects for Assistance in Transition from Homelessness (PATH) program was created to reduce or eliminate homelessness and imminent risk of homelessness for individuals with serious mental illness or co-occurring mental and substance use disorders.  The2020 Triennial Process Evaluation Report of the Projects for Assistance in Transition from Homelessness Program  (PATH)looks at the PATH program data from 2016, 2017, and 2018 to ensure that the services provided were appropriate and well-administered by the grantees. PATH is administered by the Division of State and Community Systems Development of the Center for Mental Health Services (CMHS) and the evaluation was conducted by the Center for Behavioral Health Services and Quality’s Office of Evaluation.
2015 National Survey on Drug Use and Health:  Methodological Summary and Definitions

This report summarizes methods and other supporting information that are relevant to estimates of substance use and mental health issues from the 2015 National Survey on Drug Use and Health (NSDUH), an annual survey of the civilian, noninstitutionalized population of the United States aged 12 years old or older. Section A describes the survey, including information about the sample design, data collection procedures, and key aspects of data processing (e.g., development of analysis weights). Section B presents technical details on the statistical methods and measurement, such as suppression criteria for unreliable estimates, statistical testing procedures, and issues for selected substance use and mental health measures.  Section C describes changes that were made to the 2015 NSDUH questionnaire and the effects of these changes on the comparability of estimates between 2015 and earlier years. A glossary that covers key definitions used in NSDUH reports and tables is included in Section D. Section E describes other sources of data on substance use and mental health issues, including data sources for populations outside the NSDUH target population. A list of references cited in the report (Section F) and contributors to this report (Section G) also are provided.
Mechanisms of bone loss in inflammatory arthritis: diagnosis and		  therapeutic implications

Rheumatoid arthritis represents an excellent model in which to gain			 insights into the local and systemic effects of joint inflammation on skeletal			 tissues. Three forms of bone disease have been described in rheumatoid			 arthritis. These include: focal bone loss affecting the immediate subchondral			 bone and bone at the joint margins; periarticular osteopenia adjacent to			 inflamed joints; and generalized osteoporosis involving the axial and			 appendicular skeleton. Although these three forms of bone loss have several			 features in common, careful histomorphometric and histopathological analysis of			 bone tissues from different skeletal sites, as well as the use of urinary and			 serum biochemical markers of bone remodeling, provide compelling evidence that			 different mechanisms are involved in their pathogenesis. An understanding of			 these distinct pathological forms of bone loss has relevance not only with			 respect to gaining insights into the different pathological mechanisms, but			 also for developing specific and effective strategies for preventing the			 different forms of bone loss in rheumatoid arthritis.